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Remission After Radiotherapy for a Patient
With Chemotherapy-Refractory HIV-
Associated Primary Effusion Lymphoma
A 51-year-old HIV-infected man presented with a 4-week
history of shortness of breath, right-sided chest pain, drenching
night sweats, and 5-kg weight loss. He had been diagnosed with
HIV infection 23 years previously. Investigations showed anemia
(hemoglobin, 9.8 g/d), an elevated C-reactive protein of 138.6
mg/L, a CD4 count of 550 cells/L, HIV viral load of 6800 copies/
mL, and plasma Kaposi sarcoma–associated herpes virus (KSHV)/
human herpes virus 8 (HHV8) DNA of 70,000 copies/mL. A chest
radiograph showed a moderately large right-sided pleural effusion.
He was treated empirically for atypical pneumonia. Despite a
course of antibiotics, the patient continued to complain of breath-
lessness. A chest radiograph 10 weeks later revealed a right-sided
loculated effusion and pleural thickening. A computed tomogra-
phy (CT) scan showed multiple pleural masses, the largest measur-
ing 6.8  4.3 cm, located at the right posterolateral base, a
pericardial nodule adjacent to the right atrium, a right-sided pleu-
ral effusion, and multiple small volume supraclavicular, axillary,
retroperitoneal, pelvic, and inguinal adenopathy. Biopsy of the
right base pleural mass identified a neoplastic infiltrate composed
of large lymphoid cells with irregular pleomorphic nuclei. Many of
the cells had eccentrically placed nuclei and abundant cytoplasm,
giving the tumor a plasmablastic appearance (Fig 1A). Immuno-
histochemistry demonstrated that the tumor cells were positive for
CD138 (Fig 1B), epithelial membrane antigen, and HHV8 (Fig 1C)
and showed lambda light chain restriction. Epstein-Barr virus in
situ hybridization was negative, and mindbomb homolog 1
showed a proliferation fraction of over 90%. The B-cell markers
CD20 (Fig 1D), CD79a, and paired box gene 5 were negative. The
radiologic, histologic, and serologic findings were those of HIV-
associated primary effusion lymphoma (PEL). He was commenced
on a regimen of cyclophosphamide, doxorubicin, vincristine, and
prednisolone (CHOP) chemotherapy with prophylactic intrathe-
cal methotrexate and simultaneously started on antiretroviral ther-
apy (ART; tenofovir, emtricitabine, and efavirenz). A CT scan after
six cycles of CHOP chemotherapy showed significant disease re-
sponse, with the right posterior pleural mass reduced to 4.8 3.2
cm and complete resolution of the pleural effusion. However, a
positron emission tomography/CT scan assessment after eight cy-
cles of CHOP chemotherapy showed an enlarging [18F]fluorode-
oxyglucose–avid pleural mass (5 5 cm). Biopsy of the posterior
pleural mass showed histological appearances identical to previous
biopsy, validating a diagnosis of refractory PEL. The patient started
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second-line chemotherapy with etoposide, methylprednisolone,
cytarabine, and cisplatin (ESHAP) with a view to consolidating
treatment with high-dose chemotherapy and peripheral blood
stem cells transplantation if significant disease response was
achieved. Unfortunately, CT scan assessment after two cycles of
ESHAP chemotherapy showed significant disease progression,
with the right posterior pleural base mass now measuring 7 6 cm.
He was commenced on third-line combination chemotherapy
with ifosphamide, carboplatin, and etoposide (ICE), but despite
three cycles of ICE chemotherapy, the right-sided posterolateral
chest mass continued to increase in size, measuring 11.5 7.0 cm,
and also an enlarging anterior pleural-based mass increased, now
measuring 1.6  2.1 cm. Plasma KSHV remained detectable at
20,000 copies/mL. At this stage, further chemotherapy treatment
was judged to be futile. The two masses received radiotherapy as
follows: Both had fields placed at CT-based virtual simulation. A
direct 12 MeV electron field was used for the small pleurally based
anterior mass (Fig 2A), and oblique tangential 6 MV photon field
used for the larger inferior posterolateral mass (Fig 2B). Both
received 20 Gy in 5 fractions; the former prescribed to the 90%
isodose, the latter to the mid point. A CT scan performed 4 months
after radiotherapy showed complete resolution of the large pleural
base mass (Fig 2C) and also of the anterior pleural mass. Twelve
months after completing radiotherapy, the patient remained well
and symptom free, and had a plasma KSHV DNA below the limit of
quantification ( 100 copies/mL). Overall survival since original
histological diagnosis is now 23 months.
PEL is a rare HIV-associated malignancy representing around
3% to 4% of all HIV-related non-Hodgkin’s lymphoma (NHL)
with poor clinical outcome.1,2,3 PEL is defined by serous body
cavity effusions and expression of KSHV, also known as HHV8, in
their tumor cells.1-5 Over 70% of cases display concurrent Epstein-
Barr virus infection. The optimal treatment for PEL has not yet
been defined. In most cases, patients are treated with CHOP chem-
otherapy together with introduction of highly active ART.1 Despite
this, durable responses are rarely seen and survival is short with
median survival averaging 3 to 6 months.1,4,6,7 To our knowledge,
this is the first description of a patient with HIV-associated PEL in
who radiation treatment was associated with prolonged clinical,
radiological, and serological response after failing three regimens
of systemic chemotherapy treatments. Given the chemotherapy-
refractory behavior of the disease, the dramatic response to radio-
therapy was unexpected and surprising. Our experience suggests
PEL is sensitive to radiation treatment and should be considered as
part of the treatment recommendation for patients with chemo-
therapy-refractory PEL–associated solid masses. It would also be
interesting to explore treating PEL patients with consolidation
radiation therapy for any residual histologically proven masses
following conventional CHOP chemotherapy or with total-body
irradiation, whereas the role of high-dose chemotherapy and pe-
ripheral stem-cell transplantation in refractory or relapsed HIV-
associated PEL is yet to be ascertained.8
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Chronic Lymphocytic Leukemia With Eyelid
Involvement Responding to Alemtuzumab
A 61-year-old man was diagnosed in another hematological de-
partment as having chronic lymphocytic leukemia (CLL) in 1998. One
year later, because of progressive stage II CLL characterized by dou-
bling lymphocytes count after 6 months, increase of splenomegaly,
and the appearance of B symptoms, the patient was treated with
fludarabine, obtaining partial remission of disease. Starting from
2000, due to progression of disease, the patient underwent a cyclo-
phosphamide, doxorubicin, vincristine, and prednisolone regimen
plus interferon- as maintenance therapy for 2 years; thereafter the
successive relapse was treated with chlorambucil plus metilpred-
nisolone in 2003 and chlorambucil in 2005, respectively. In January
2006, he presented lymphoadenopaties between 1.5 and 2.5 cm in his
right armpit, and inguinal bilaterally inferior margin of spleen 2 cm
after the costs margin, absent of B symptoms. A total-body computed
tomography scan confirmed multiple lympoadenomegalies in the
mediastinum, abdomen, and splenomegaly. An emocromocytomet-
ric analysis presented a WBC of 27,280/mm3 (neutrophil, 2,000/mm3;
leukocyte, 23,000/mm3); hemoglobin of 14.3 g/dL; medium cellular
volume of 84.6 fl; and platelets of 204  109/L. A peripheral blood
smear showed more than 50% of big lymphocytes (its size was double
in respect to erythrocyte size); for these reasons we classified this form
as atypical chronic lymphocytic leukemia (mixed CLL). Bone marrow
aspiration showed 55% of infiltration by mature lymphocytes, and a
bone marrow biopsy confirmed the same diffuse infiltration. Cyt-
ofluorimetric analysis of peripheral blood showed positivity for CD5,
CD5/CD19, CD23, and ; at the same time the positivity of CD38
(73%) and ZAP-70 (41%) was detected. Fluorescent in situ hybridiza-
tion analysis showed trisomy of chromosome 12, as expected by mor-
phological analysis and 17p deletion. The mutational status of variable
region of heavy chain immunoglobin discovered a mutated status
(variable heavy chain 3-49). Because of stable stage II disease with bad
biologic parameter in theheavily pretreated patient, a stringent
follow-up was adopted. In October 2006, at routine check-up, the
patient showed a bilateral painless nodular infiltration of the eyelids,
similar to multiple chalazions. Two nodules were localized in each
Fig 1.
Diagnosis in Oncology
www.jco.org © 2008 by American Society of Clinical Oncology 5299
Copyright © 2008 by the American Society of Clinical Oncology. All rights reserved. 
193.60.226.1. 
Information downloaded from jco.ascopubs.org and provided by UCL Library Services on December 3, 2008 from
